Introduction
============

K~V~7 channels underlie the so-called 'M'-current, a subthreshold active neuronal K^+^ current ([@b1]). All five known subtypes (K~V~7.1--7.5) are likely to be expressed in central neurons ([@b1]; [@b7]). Although early reports indicated that these neurons may have a somato-dendritic expression pattern ([@b23]; [@b26]), recent reports suggest that these channels are expressed at a higher density in axons ([@b6]; [@b2]; [@b19]). Here, they play a role in regulating the resting membrane potential and action potential threshold ([@b25]), and thereby influence post-synaptic spike firing. This may be one of the potential mechanisms that enhance neuronal excitability during benign familial neonatal convulsions (BFNC) as mutations in K~V~7/M-channels associated with this condition can result in disrupted axonal K~V~7 channel function ([@b2]).

*In vivo*, though, excitatory synaptic potential (EPSP) integration is an important factor in determining action potential generation ([@b4]; [@b3]). Since K~V~7 channels are active at rest ([@b25]), it is possible that they may contribute to synaptic potential integration. Indeed, the summation of a train of EPSPs generated by extracellular stimulation in hippocampal CA1 pyramids is affected by K~V~7/M-channel modulation ([@b9]). However, since K~V~7/M-channels may also be present pre-synaptically in the hippocampus ([@b15]; [@b20]), it is not clear whether this effect is pre- or post-synaptic in origin. In this study, we injected EPSP waveforms (αEPSPs) in the soma and dendrites of CA1 pyramids to investigate how EPSP integration is affected in these neuronal subcellular compartments. We also used a competing peptide, ankyrin G binding peptide (ABP; [@b25]) to determine if axonal K~V~7 channels contribute to somatic EPSP summation. Computer simulations were performed to corroborate our findings. We show that somatic, but not axonal, K~V~7/M-channels affect synaptic integration in a voltage-dependent manner in peri-somatic locations only. Axonal K~V~7 channels, on the other hand, alter EPSP--spike coupling by lowering the action potential threshold. Modulation of EPSP--spike coupling may be another mechanism by which modification in K~V~7/M-channel function may have a substantial impact on neuronal excitability and therefore, physiological processes such as learning and memory as well as patho-physiological conditions such as epilepsy ([@b11]; [@b21]; [@b28]).

Methods
=======

Ethical approval
----------------

All experimental procedures were approved by the UK Home Office (Project licence PPL No. 70/06372) as well as the School of Pharmacy and UCL research ethics committees.

Electrophysiological studies
----------------------------

Methods used were similar to those described previously (see ([@b25]). Briefly, 5- to 6-week-old rats were anaesthetized and perfused intracardially with ice-cold modified ACSF containing (in m[m]{.smallcaps}): 110 choline chloride, 2.5 KCl, 1.25 NaH~2~PO~4~, 25 NaHCO~3~, 0.5 CaCl~2~, 7 MgCl~2~ and 10 glucose, and bubbled continuously with 95% O~2~--5% CO~2~ to maintain pH at 7.2. Hippocampal--entorhinal slices, 400 μm thick, were prepared using a vibratome (Leica VT1000S). The slices were incubated in a holding chamber for 1 h at room temperature in external solution of the following composition (in m[m]{.smallcaps}): 125 NaCl, 2.5 KCl, 1.25 NaH~2~PO~4~, 25 NaHCO~3~, 2 CaCl~2~, 2 MgCl~2~ and 10 glucose, and bubbled continuously with 95% O~2~--5% CO~2~ to maintain pH at 7.2. Whole-cell current-clamp recordings were obtained from both the soma and dendrites of CA1 pyramidal neurons. For recording purposes, slices were placed in a chamber containing external solution supplemented with 0.05 m[m]{.smallcaps} APV, 0.01 m[m]{.smallcaps} CNQX, 0.01 m[m]{.smallcaps} bicuculline and 0.001 m[m]{.smallcaps} CGP 55845 and maintained at 34--36°C. The internal pipette solution contained (in m[m]{.smallcaps}): 120 KMeSO~4~, 20 KCl, 10 HEPES, 2 MgCl~2~, 0.2 EGTA, 4 Na~2~-ATP, 0.3 Tris-GTP and 14 Tris-phosphocreatine; pH was adjusted to 7.3 with KOH. Pipettes containing this internal solution had resistances of 8--9 MΩ. Whole-cell current-clamp recordings were obtained using a bridge-mode amplifier (Axoclamp 2A), filtered at 10 kHz and sampled at 30 kHz. Series resistances were usually of the order of 10--15 MΩ. Simulated EPSPs (αEPSPs) were generated by current injection of the order:

where *A* is the amplitude of the current injected and τ is the rise time constant. All M-channel (KCNQ/Kv7) modulators were bath applied. All recordings were acquired using pCLAMP 8.0 and stored on a computer for further analysis.

Data analysis
-------------

All measurements were made using Clampfit (v8.0). The summation ratio was calculated as the amplitude of the fifth EPSP divided by the amplitude of the first. Group data are expressed as mean ± SEM. Statistical significance was determined using either paired or unpaired Student\'s *t* tests as appropriate. Statistical significance of *P* \< 0.05 is indicated as \* in all figures.

Materials
---------

All chemicals were obtained from Sigma (St Louis, MO, USA) apart from XE991, CNQX, CGP 55845, bicuculline and APV, which were purchased from Tocris (USA). Retigabine was provided by NeuroSearch (Ballerup, Denmark) through EU grant LSHM-CT-2004-503038. ABP and sABP was custom made by Genscript (USA). Stock solutions of bicuculline and CGP 55845 were made in DMSO and stored at −20°C until use. These were then dissolved in the external solution such that the final DMSO concentration was less than 0.1%. Aqueous stock solutions of XE991, linopirdine, CNQX and APV were also kept at −20°C until use.

Computational modelling methods
-------------------------------

All simulations were implemented and run with the NEURON program (v7.1) ([@b8]) using the variable time step feature. The 3D reconstruction of the CA1 pyramidal neuron was one of those used in a previous work (neuron 9068802, [@b16]). The same standard, uniform, passive properties were used for control conditions (τ~m~ = 28 ms, *R*~m~ = 28 kΩ cm^2^, *R*~a~ = 150 Ω cm). Resting potential was set at −65 mV and at 35°C. All channel kinetic and distribution were from a previously published model ([@b25]), and based on the available experimental data for CA1 pyramidal neurons (reviewed in [@b18]). Sodium and delayed rectifier potassium conductances were uniformly distributed throughout the dendrites, whereas an A-type potassium and a non-specific *I*~h~ conductance were linearly increasing with distance from the soma. The K~V~7-type potassium conductance was inserted into the soma and at a 3-fold higher density in the axon ([@b25]). To take into account for Ca^2+^ channels open around resting potential (reviewed in [@b14]), a low-threshold Ca^2+^ and Ca^2+^-dependent K*^+^* conductances together with a simple Ca^2+^ extrusion mechanism were included at uniform density and distribution in all compartments. The simulation files are available for public download under the ModelDB section ([@b17]) of the Senselab database (<http://senselab.med.yale.edu>). The effects of XE991 application were modelled by deleting the K~V~7/M-conductance.

Results
=======

To determine if Kv7 (M-) channels affect post-synaptic EPSP kinetics and summation at the soma and dendrites, individual EPSPs as well as 20 and 40 Hz trains of EPSPs were induced post-synaptically by injecting an alpha waveform current ([@b22]; [@b24]) (see Methods) into either the soma or dendrite. These somatic and dendritic αEPSPs had similar kinetics to those evoked by stimulating the Schaffer collaterals in the stratum radiatum. We chose this method to avoid complications due to possible pre-synaptic effects of K~V~7 channels ([@b15]; [@b20]; [@b12]; [@b10]). Experiments were done in the presence of 1 μ[m]{.smallcaps} TTX to prevent spontaneous action potential firing in the presence of the K~V~7/M-channel inhibitor, XE991 ([@b25]). At −60 mV, 3 μ[m]{.smallcaps} XE991 enhanced the amplitude of somatic αEPSPs by 34.7 ± 11% (*n* = 6, *P* \< 0.05, [Fig. 1*A*](#fig01){ref-type="fig"}) and lengthened the decay time constant (τ) by 92.3 ± 28% (*n* = 6, *P* \< 0.05, [Fig. 1*A*](#fig01){ref-type="fig"}). Consistent with the M-current biophysical properties in these neurons ([@b25]), the actions of XE991 were voltage dependent with significantly smaller effects at −70 mV (% change in amplitude and τ were 23.2 ± 3.1% (*n* = 6) and 28.7 ± 7.4% (*n* = 6, *P* \< 0.05), respectively, [Fig. 1*A*](#fig01){ref-type="fig"}). The K~V~7/M-channel enhancer, retigabine (10 μ[m]{.smallcaps}), on the other hand, had little effect on somatic αEPSP amplitudes at either −70 mV or −60 mV ([Fig. 1*B*](#fig01){ref-type="fig"}). It significantly reduced τ at −60 mV by 41.8 ± 3.8% (*n* = 9, *P* \< 0.05) but not at −70 mV ([Fig. 1*B*](#fig01){ref-type="fig"}). Neither retigabine nor XE991 had any effect on dendritic αEPSPs ([Fig. 1*A* and *B*](#fig01){ref-type="fig"}), as would be expected for a significantly lower dendritic K~V~7 channel density ([@b29]; [@b9]; [@b25]).

![Example traces showing the effects of (*A*) the K~V~7/M-channel blocker XE991 (3 μ[m]{.smallcaps}) and (*B*) the K~V~7/M-channel enhancer retigabine (10 μ[m]{.smallcaps}) on simulated EPSP (αEPSP) shapes at the soma and dendrites when evoked at a potential of −60 mV\
Black traces represent controls whereas the grey traces are those obtained following bath application of the K~V~7/M-channel modulator. Shown below the traces are the average (mean and SEM) somatic and dendritic αEPSP amplitudes in the absence and presence of (*A*) XE991 and (*B*) retigabine at potentials of −60 mV and −70 mV. The observations for each point are indicated in brackets next to the potential. Within each panel, the percentage change in the decay time constant (τ) of αEPSPs at the soma and dendrites at either −60 mV or −70 mV is illustrated in the graph on the far right. In these particular graphs, the numbers of observations are indicated above each bar. \*Significance at *P* \< 0.05.](tjp0589-6029-f1){#fig01}

Since the K~V~7 modulators affected somatic αEPSP decay time constants at −60 mV, it is likely that they may also modulate αEPSP integration at that voltage. Indeed, at −60 mV XE991 and retigabine significantly enhanced and reduced, respectively, the summation of 20 Hz and 40 Hz trains of somatic 5 αEPSPs ([Fig. 2*A* and *B*](#fig02){ref-type="fig"}). Removal of TTX, in the presence of XE991, resulted in spikes during the somatic αEPSP train irrespective of the frequency, indicating that EPSP--spike coupling had increased (data not shown).

![Representative illustrations showing trains of 20 Hz or 40 Hz somatic and dendritic αEPSPs in the absence (black) and presence (grey) of either (*A*) 3 μ[m]{.smallcaps} XE991 or (*B*) 10 μ[m]{.smallcaps} retigabine at a potential of −60 mV\
The summation ratio was calculated as the amplitude of the fifth αEPSP divided by the amplitude of the first αEPSP (see Methods). Below each of the examples are graphs showing the mean and SEM of the summation ratio for the particular frequency at potentials of either −60 mV or −70 mV. The numbers of observations for each frequency at a particular potential are indicated in parentheses within each graph. \*Significance at *P* \< 0.05.](tjp0589-6029-f2){#fig02}

Interestingly, retigabine, unlike XE991 ([Fig. 2*A*](#fig02){ref-type="fig"}), affected somatic αEPSP summation at −70 mV ([Fig. 2*B*](#fig02){ref-type="fig"}). The effects were less than that at −60 mV ([Fig. 2*B*](#fig02){ref-type="fig"}), consistent with the much reduced effect of the compound on the decay time constants of single αEPSPs ([Fig. 1*B*](#fig01){ref-type="fig"}). Retigabine shifts the activation curve of K~V~7/M-current to the left in neurons ([@b27]; [@b25]). Hence, in the presence of retigabine, channel opening occurs at lower voltages and so summation is likely to be more affected by retigabine at −70 mV than by XE991.

Neither XE911 nor retigabine altered dendritic αEPSP summation ([Fig. 2*A* and *B*](#fig02){ref-type="fig"}), in agreement with the lack of effects of the compounds on single dendritic αEPSPs and the notion that fewer K~V~7 channels are located in dendrites ([@b29]; [@b9]; [@b25]).

To verify the interpretation of the above results, we performed computer simulations using a model that we had previously found best mimicked the changes in firing patterns of CA1 neurons following K~V~7 channel inhibition (see [@b25]). Na^+^ channels were not included in these simulations as in our experimental conditions Na^+^ channels had been inhibited by TTX. Compatible with the experimental results, K~V~7 channel deletion throughout the neuron enhanced 20 Hz ([Fig. 3*A*](#fig03){ref-type="fig"}) and 40 Hz EPSP summation at the soma at −60 mV. The increase in summation was less than at −70 mV ([Fig. 3*A*](#fig03){ref-type="fig"}), consistent with the biophysical properties of K~V~7 channels in hippocampal pyramidal cells ([@b25]). Dendritic EPSP summation, though, was not affected at either frequency at −60 mV or −70 mV ([Fig. 3*B*](#fig03){ref-type="fig"} for example traces at 20 Hz). These findings support the idea that K~V~7 channels are principally located at the soma/axon and affect peri-somatic post-synaptic EPSP integration.

![Twenty hertz trains of EPSPs obtained using computer simulations with (black) and without (red) K~V~7/M-channels at the soma (*A*) and dendrites (*B*)\
The simulations were obtained at −70 mV and −60 mV. *C*, computer simulations showing 20 Hz αEPSP traces under control (black) conditions and following the selective removal of either somatic or axonal K~V~7/M-channel density (grey). The simulations were performed at −60 mV. The scale bar shown applies to both traces.](tjp0589-6029-f3){#fig03}

We next asked whether axonal or somatic K~V~7 channels differentially affect EPSP integration. In computer simulations, removal of axonal K~V~7 channels but leaving somatic channels intact, had little impact on EPSP summation at the soma ([Fig. 3*C*](#fig03){ref-type="fig"}). In contrast, elimination of somatic K~V~7 channels with axonal K~V~7 channels still present significantly enhanced summation ([Fig. 3*C*](#fig03){ref-type="fig"}). These results indicate that only somatic K~V~7 channels affect peri-somatic EPSP summation.

To test if this is so experimentally, we used a competing peptide, ABP (YIAEGESDTD), that is designed to selectively disrupt the coupling of K~V~7 channels to ankyrin G, and thereby alter K~V~7 channel function in the axon (see [@b25]). Hence, unlike XE991 or retigabine, bath application of which would affect all channels within the neuron, this peptide only affects axonal K~V~7 channels. Indeed, we have previously shown that the peptide had little effect on somatic M-current measured with voltage clamp ([@b25]). Inclusion of this peptide (10 m[m]{.smallcaps}) in the intracellular pipette solution caused RMP depolarization from −68 ± 0.7 mV to −60.9 ± 1.4 mV (*n* = 8, *P* \< 0.05) within 25 min ([Fig. 4*A*](#fig04){ref-type="fig"}). The action potential threshold was also lowered by 4.9 ± 1.3 mV (*n* = 7, *P* \< 0.05, [Fig. 4*A*](#fig04){ref-type="fig"}) as described previously ([@b25]). As a consequence, the action potential firing rate increased substantially, with 5 out of 8 neurons firing spontaneously as reported previously ([@b25]). However, unlike XE991 ([@b9]; [@b25]), the somatic input resistance as measured using a 400 ms, 50 pA depolarizing step from a fixed potential of −70 mV was unaffected by ABP (% change = −2.9 ± 22.6%, *n* = 7). Inclusion of a scrambled ABP (TSEYDAEDIG, 10 m[m]{.smallcaps}) had little effect on resting membrane potential ([Fig. 4*B*](#fig04){ref-type="fig"}), action potential firing ([Fig. 4*B*](#fig04){ref-type="fig"}), action potential threshold ([Fig. 4*B*](#fig04){ref-type="fig"}) or input resistance (% change = 13.9 ± 21.8%, *n* = 3) over a period of 45--60 min.

![Effects of ABP and sABP on action potential firing and resting membrane potential\
*Aa, Ba, Ab* and *Bb*, examples of traces 5 min and 25 min after obtaining whole-cell patch clamp when ABP (*A*) or sABP (*B*) is included in the patch pipette solution. *Ac* and *Bc*, representative traces showing the influence of ABP and sABP on action potential threshold 5 min (black) and 25 min (grey) after breakthrough. The alterations in resting membrane potential, the number of action potentials and the action potential threshold when either ABP or sABP are present in the patch pipette are shown in *Ad, Bd, Ae, Be, Af* and *Bf*. In panels *Af* and *Bf*, the filled squares represent the mean and standard error whereas the open squares show the individual responses.](tjp0589-6029-f4){#fig04}

We then tested the effects of ABP on single and trains of αEPSPs generated at the soma. In contrast to XE991 ([Fig. 1*A*](#fig01){ref-type="fig"}), in the presence of TTX, single αEPSPs were unaffected by ABP at −60 mV (% increase in amplitude and τ = 4.3 ± 12.0% (*n* = 4) and −6.5 ± 10.7% (*n* = 4), respectively). Thus, not surprisingly, trains of 20 Hz and 40 Hz αEPSPs were unaffected by 30 min ABP treatment at −60 mV ([Fig. 5*A*](#fig05){ref-type="fig"}). Removal of TTX resulted in action potentials being elicited in 60% (3/5) of neurons with 40 Hz αEPSP trains and in 50% (2/4) of neurons with 20 Hz αEPSP trains ([Fig. 5*A*](#fig05){ref-type="fig"}), presumably because ABP lowers the action potential threshold ([Fig. 4*A*](#fig04){ref-type="fig"}). Inclusion of scrambled ABP (sABP) in the pipette solution for 45 min had no effect on single (% increase in amplitude and τ = 9.2 ± 12.3% (*n* = 6, *P* = 0.7) and 9.0 ± 14.7% (*n* = 6, *P* = 0.4), respectively) or trains of αEPSPs (*n* = 6, [Fig. 5](#fig05){ref-type="fig"}). Further, washing out TTX did not result in spikes with αEPSP trains if sABP was included in the patch pipette. Hence, disruption of axonal or somatic K~V~7 channel function is likely to alter EPSP--spike coupling. However, only somatic K~V~7 channels affect EPSP integration at the soma.

![Axonal K~V~7 channels have little effect on somatic αEPSP summation\
*A*, example traces showing the effects of including the ankyrin G binding peptide (ABP, 10 m[m]{.smallcaps}) in the intracellular pipette solution on 20 Hz and 40 Hz trains of αEPSPs. The traces within 5 min of going whole cell are deemed control (see ([@b25]) and are in black. The maximal effect of ABP occurs within 25 min ([@b25]) and is shown in red. TTX was present throughout. Washout of TTX resulted in spikes (AP; green trace). Generation of spikes will cause an afterdepolarization and/or afterhyperpolarization, which will affect αEPSP summation. Indeed, in the particular example shown, the action potential resulted in an afterdepolarization followed by an afterhyperpolarization, thereby distorting the αEPSP summation. For this reason, αEPSP summation ratios were calculated from traces in the which TTX was present in the external solution. The average (mean and SEM; filled squares) and individual (open squares) calculated summation ratios following 5 min and 25 min of patching with pipettes containing ABP in the presence of external TTX are shown below the traces. *B*, representative traces showing the effects of scrambled ABP (sABP, 10 m[m]{.smallcaps}) on 20 Hz and 40 Hz trains of αEPSPs within 5 min of going whole cell (control, black) or after 25 min (red). All experiments were performed in the presence of TTX. The individual (open squares) and mean (filled squares) calculated summation ratios for all cells in which sABP was included in the pipette are shown below.](tjp0589-6029-f5){#fig05}

Discussion
==========

Post-synaptic K~V~7/M-channels have been shown to modulate action potential firing in a number of different cell types (pyramidal neurons as well as interneurons; [@b1]). Here, we show that post-synaptic K~V~7 channels also affect synaptic integration in a location-dependent manner in CA1 pyramids. Bath application of K~V~7 channel modulators affected somatic but not dendritic synaptic potential shapes ([Fig. 1](#fig01){ref-type="fig"}) and summation ([Fig. 2](#fig02){ref-type="fig"}) in a voltage-dependent manner, in agreement with the reported biophysical properties of the M-current in hippocampal CA1 pyramids ([@b25]). These results were reproducible by computer modelling ([Fig. 3](#fig03){ref-type="fig"}). Hence, K~V~7/M-channels are likely to be primarily located in the peri-somatic region ([@b29]; [@b9]; [@b25]).

In our experiments, most synaptic transmission was blocked. K~V~7/M-channels may be present on pre-synaptic terminals in the hippocampus ([@b15]; [@b20]). Therefore, though post-synaptic K~V~7/M-channels do not affect dendritic synaptic potentials directly, modulation of synaptic release by pre-synaptic K~V~7/M-channels may additionally affect dendritic excitability and synaptic integration.

K~V~7/M-channels are likely to be present predominantly in the axon initial segment ([@b6]; [@b2]; [@b19]; [@b25]). However, our data suggested that only somatic channels altered somatic synaptic potential shapes and summation as bath application of XE991 and retigabine (which would affect all K~V~7 channels in a neuron) modified somatic EPSP summation ([Fig. 2](#fig02){ref-type="fig"}) whereas use of the competing peptide, ABP, had little effect ([Fig. 5](#fig05){ref-type="fig"}). In these neurons, ABP modulates only axonal K~V~7 channels as it lowered the action potential threshold without changing the input resistance ([Fig. 4](#fig04){ref-type="fig"} and Results). In contrast, treatment with XE991, which would inhibit all K~V~7 channels, reduced the action potential threshold and increased the input resistance (see [@b25]). Further, we have previously shown that bath application of XE991 after ABP has had its full effect causes little further decrease in action potential threshold ([@b25]). These data thus suggest that ABP affects axonal K~V~7 channels only. In addition, the notion that somatic but not axonal K~V~7 channels affected summation was supported by data obtained using computer simulations ([Fig. 3*C*](#fig03){ref-type="fig"}). Since somatic K~V~7 channels influence somatic input resistance ([@b25]), and variations in input resistance lead to changes in synaptic potential shapes ([@b13]), this may explain why only K~V~7 channels located at the cell body modified synaptic integration. These results therefore suggest that the effects of K~V~7 channels on synaptic integration are locally mediated. Since recent evidence suggests synaptic potentials can propagate along axons ([@b3]), we cannot exclude the possibility that axonal K~V~7 channels may influence shapes and summation of synaptic potentials within these structures. Indeed, recent evidence shows that K~V~7 channels located in immature synaptic terminals alter inhibitory depolarizing synaptic potential shapes and integration in the bouton, suggesting that K~V~7 channels exert a local effect on synaptic integration within a particular neuronal subcellular compartment ([@b10]).

By modulating spike threshold and the resting membrane potential of neurons ([Fig. 4](#fig04){ref-type="fig"}; [@b25]), axonal K~V~7 channels can affect global cell excitability too. Thus, though ABP did not affect somatic synaptic integration *per se*, EPSP--spike coupling was enhanced as the action potential threshold was reduced ([Fig. 5](#fig05){ref-type="fig"}). This also raises the possibility that the manner in which K~V~7 channels affect cell excitability may depend on the cellular compartment in which they are expressed. Since these channels are modulated by a variety of neurotransmitters and intracellular signalling molecules ([@b5]), this may provide an exquisite mechanism by which K~V~7 channels can fine-tune a cell\'s intrinsic activity in response to changing neural network excitability and thereby influence physiological processes such as plasticity and learning as well as prevent neurological disorders such as epilepsy ([@b11]; [@b21]; [@b28]).
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:   simulated EPSP waveform
